Initial choices and final outcomes in lower urinary tract symptoms

European Urology

Volumn 40, Issue SUPPL. 4, 2001, Pages 21-30

  Speakman, Mark J ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

1 Adrenoceptor antagonists; BPH; Evidence based medicine; Finasteride; LUTS; Transurethral resection of the prostate; Watchful waiting

Indexed keywords

ALFUZOSIN; FINASTERIDE; INDORAMIN; PRAZOSIN; SABAL EXTRACT; TAMSULOSIN; TERAZOSIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SURGICAL TECHNIQUE; SYMPTOM; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; URETHRA; URINARY DYSFUNCTION; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; SULFONAMIDES; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URINARY RETENTION;

EID: 0035682151     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049891     Document Type: Conference Paper

References (69)

1. Who should be treated and how? Evidence-based medicine in symptomatic BPH
2. Evidence-based disease management
3. Getting research findings into practice. Barriers and bridges to evidence based clinical practice
4. Benign prostatic hyperplasia
5. Treatment options for benign prostatic hyperplasia
6. Lower urinary tract symptoms suggestive of benign prostatic obstruction: What is the available evidence for rational management?
7. The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction
8. Measuring disease-specific health status in men with benign prostatic hyperplasia
9. The American Urological Association symptom index for benign prostatic hyperplasia
10. Urinary symptoms in the community: How bothersome are they?
11. Implications of the most bothersome prostatism symptom for clinical care and outcomes research
12. The International Continence Society 'Benign Prostatic Hyperplasia' Study: The bothersomeness of urinary symptoms
13. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community
14. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia
15. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement
16. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years
17. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists
18. Natural history of prostatism: Urinary flow rates in a community-based study
19. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention
20. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting
21. Natural history of prostatism: Risk factors for acute urinary retention
22. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
23. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: Comparative study with prazosin
24. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)
25. 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
26. Clinical comparison of selective and non-selective alpha1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients
27. Results of the PREDICT (Prospective Randomised European Doxazosin and Combination Therapy) trial
28. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
29. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia
30. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
31. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes
32. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia - Related outcomes and long-term response to finasteride
33. Lower urinary tract symptoms suggestive of benign prostatic obstruction. What's the long-term effectiveness of medical therapies?
34. Benign prostatic obstruction complications and need for surgery
35. Alfuzosin for treatment of benign prostatic hypertrophy
36. A 6-months large-scale study into the safety of tamsulosin
37. How do symptoms indicative of BPH progress in real life practice? The UK experience
38. Sustained-release alfuzosin and trial without catheter after acute urinary retention: A prospective, placebo-controlled trial
39. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: A randomized, prospective clinical trial
40. Temporal resolution of urinary morbidity following prostate brachytherapy
41. Incidence and risk reduction of long-term outcomes: A comparison of benign prostatic hyperplasia with several other disease areas
42. Medical therapy for benign prostatic hyperplasia: A review of the literature
43. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
44. Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning
45. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia
46. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: Results of a pilot study
47. Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia
48. The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia
49. The National Prostatectomy Audit: The clinical management of patients during hospital admission
50. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study
51. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The ClasP study
52. Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients
53. A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The ClasP study
54. Does evaluation with the international prostate symptom score predict the outcome of transurethral resection of the prostate?
55. The Oxford Laser Prostate Trial: A double-blind randomized controlled trial of contact vaporization of the prostate against transurethral resection; preliminary results
56. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
57. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial
58. Tamsulosin: Real life clinical experience in 19,365 patients?
59. Low incidence of acute urinary retention during tamsulosin treatment
60. Improvement of pressure flow parameters with finasteride is greater in men with large prostates
61. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response
62. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options
63. Patient reports of symptoms and quality of life following prostate surgery
64. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms
65. The follow-up of patients with unfavourable early results of transurethral prostatectomy
66. The American Urological Association Symptom Index: Early postoperative evaluation of irritative and obstructive symptoms due to benign prostatic hyperplasia
67. 3-Year follow-up of urinary symptoms after transurethral resection of the prostate
68. Tamsulosin versus tamsulosin and Serenoa Repens in patients with LUTS suggestive of BPO